VTAK Company Profile and Key Details

VTAK has shown mixed momentum, gaining 3.98% over the past week and -19.31% over the past quarter, though year-to-date performance is up 14.21%. Short-term trend indicators are bullishly aligned (SMA20 -6.27%, SMA50 -14.47%, SMA200 -46.08%). The stock’s 14-day RSI is 43.61 (neutral), while the ATR of 0.17 points to higher daily volatility. The stock remains hovering near 52-week lows, trading -89.6% below its high and over 42.98% above its low. Average 10-day trading volume of 19.19 thousand shares is below the 3-month average of 79.43 thousand, indicating normal recent market interest.

Catheter Precision, Inc. generated EPS of -$41.40 over the past year. Five-year average earnings growth is 83.47%. Catheter Precision, Inc. earnings surprise history is a mixed track record. The quarter that ended November 13, 2025, missed forecasts by -93.61%. The prior quarter beat by -78.89%. Over the last six quarters, Apple has recorded several small beats. These include 111.79% in August 14, 2024.

Catheter Precision, Inc. has 1.23 million shares outstanding. The public float is 1.20 million shares, elevated short interest at 6.46% of float. This equals 78.47 thousand shares. The short ratio is 0.03 days. Institutional investors hold 3.63% of the float. Insiders own 1.67%.

Catheter Precision, Inc. last paid a dividend of 0 per share, Dividend and splits history remains an important factor for investors monitoring long-term returns. A discounted cash flow model estimates fair value at around -$3.42. This means the shares are trading below this model’s fair value.

Catheter Precision, Inc. (AMEX:VTAK) closed at $1.37 USD, losing -$0.04 (-2.84%) from the previous close of $1.41. The stock is currently mid-range between its 52-week high and low $1.14 and $15.77. With a market capitalization of about $1.68 million, Catheter Precision, Inc. is classified as a micro-cap and shows lower-than-market volatility (beta ~-0.16). Key stats such as the average daily volume over the past year has been around 78.79 thousand shares, volume is running light vs its 52-week average. Headquartered in Fort Mill, SC, Catheter Precision, Inc. operates in the Healthcare sector and the Medical - Devices industry. Led by CEO David A. Jenkins, the company employs approximately 22 people and listed since September 27, 2018. Catheter Precision, Inc. develops and delivers electrophysiology products to provide patients, hospitals, and physicians with technologies and solutions to improve the lives of patients with cardiac arrhythmias in the United States.

Catheter Precision, Inc. trades at a P/E ratio of -1.06, slightly below the S&P 500 average, with a price-to-sales ratio of 2.36 and a price-to-book ratio of 2.73 suggesting the stock is closer to book value. The P/FCF stands at -0.18, also below market averages.

Our AI price prediction model suggests that Catheter Precision, Inc. stock has strong potential for upside but may face short-term weakness followed by gains in the medium and long term. 2-Week Outlook: Projected decline of -12.41%, with price expected at $1.20 by March 20, 2026, within a range of $1.03 to $1.37 3-Month Outlook: Projected fall of -78.83%, reaching $0.29 by June 04, 2026, with a range of $0.00 to $0.76. 1-Year Outlook: Projected loss of -100.0%, with price at $0.00 by March 05, 2027, within a range of $0.00 to $6.58.

Catheter Precision, Inc. (AMEX:VTAK) shares are up 14.21% year-to-date currently trading near 52-week highs band. Short-term momentum has been negative over the last quarter, despite recent volatility. Valuation shows Catheter Precision, Inc. trading at a premium to the broader market with a P/E of -1.06. Our AI forecast model points to short-term weakness (-12.41% over two weeks), a medium-term fall (-78.83% over three months), and a longer-term loss (-100.0% over one year), with expected trading ranges indicating moderate volatility.